Erythropoietin (EPO) is a very important agent for the treatment of anemias resulting from compromised EPO production. EPO plays essential roles in stimulating the growth and differentiation of erythroid progenitors during erythropoiesis. Although EPO is important for the treatment of human diseases, a little is known about the mechanisms of this agent. For instance, how it regulates growth and differentiation is poorly understood. It is the goal of this proposal to understand how EPO binding to its receptor leads to be the induction of genes such as oncogenes associated with growth and differentiation. EPO has been shown to alter protein phosphorylation on serine through activation of PK-C. Preliminary results from our laboratory demonstrate that EPO also modulates phosphorylation on tyrosines. In addition, we have demonstrated that EPA activates the activity of JUN/AP-1 enhancer element placed in front of CAT gene. Activation of both PK-C and AP-1 sequence by PMA and growth factors are associated with regulation of differentiation. In this proposal, we will examine (1) whether EPO activates FOS and JUN RNA and protein synthesis; (2) whether EPO activates c-jun transcription through the AP-1 sequence; (3) whether overexpression of c-jun is enough to induce differentiation of K562 and Rauscher cells; (4) determine whether EPO stimulates the transcription of Jun B and Jun D genes; (5) identify signal transduction molecules involved in mediating EPO's signal to the nucleus; and, (6) determine the role of AP-1 activation in regulation of globin gene synthesis by EPO. The knowledge to be obtained from this project will enable us to use EPO more effectively in the treatment of diseases and to block its activity when it functions to promote growth of neoplastic cells.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL038737-10
Application #
6109892
Study Section
Project Start
1997-04-01
Project End
2001-03-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
10
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Meharry Medical College
Department
Type
DUNS #
City
Nashville
State
TN
Country
United States
Zip Code
37208
Burch-Sims, G Pamela; Matlock, Valeria R (2005) Hearing loss and auditory function in sickle cell disease. J Commun Disord 38:321-9
Aguinaga, M D; Kutlar, F; Turner, E A et al. (2000) Hb Inkster [alpha85(F6)Asp-->Val] found in a caucasian male with polycythemia. Hemoglobin 24:333-9
Shokrani, M; Terrell, F; Turner, E A et al. (2000) Chromatographic measurements of hemoglobin A2 in blood samples that contain sickle hemoglobin. Ann Clin Lab Sci 30:191-4
Popp, R A; Shinpock, S G; Qopp, D M et al. (1998) Erythropoietin level and effect of rHuEPO in beta-thalassemic mice. Ann N Y Acad Sci 850:455-8
Iyamu, E W; Roa, P D; Kopsombut, P et al. (1998) New isocratic high-performance liquid chromatographic procedure to assay the anti-sickling compound hydroxyurea in plasma with ultraviolet detection. J Chromatogr B Biomed Sci Appl 709:119-26
Roa, D; Kopsombut, P; Aguinaga, M P et al. (1997) Hydroxyurea-induced denaturation of normal and sickle cell hemoglobins in vitro. J Clin Lab Anal 11:208-13
Roa, D; Turner, E A; Aguinaga, M D (1995) Reference ranges for hemoglobin variants by HPLC in African Americans. Ann Clin Lab Sci 25:228-35
Robbins, V; Aguinaga, M P; Valenzuela, M S (1995) Efficient isolation of whole genomic DNA from cell cultures and blood samples. Biotechniques 18:414-6, 418
Roa, P D; Turner, E A; Aguinaga, M del P (1993) Hemoglobin variant detection from dried blood specimens by high performance liquid chromatography. Ann Clin Lab Sci 23:433-8
Chakrabarti, A; Sitaric, S; Ohi, S (1992) A procedure for large-scale plasmid isolation without using ultracentrifugation. Biotechnol Appl Biochem 16:211-5

Showing the most recent 10 out of 17 publications